FDA Approves Sanofi’s Subcutaneous Isatuximab (Sarclisa Escena) for Multiple Myeloma, Enhancing Patient Convenience

July 26, 2026

Drugs.com USA

Overview

The U.S. FDA has approved Sanofi’s subcutaneous formulation, Sarclisa Escena (isatuximab-irfc), for multiple myeloma, significantly improving administration convenience for patients. This new formulation reduces treatment burden compared to the existing intravenous version, potentially boosting patient adherence and quality of life. The approval offers a more flexible treatment option, enabling administration at home or in a clinic setting.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has granted approval for Sarclisa Escena (isatuximab-irfc), a subcutaneous (SC) formulation of Sanofi’s multiple myeloma drug, isatuximab. This approval is a significant advancement in patient care, offering a more convenient and less time-consuming administration option compared to the previously available intravenous (IV) formulation.

Technical / Clinical Details

Isatuximab is a monoclonal antibody that targets the CD38 antigen expressed on multiple myeloma cells. CD38 is also found on some immune cells, and the antibody’s binding leads to the destruction of these cells, inhibiting myeloma progression. Historically, isatuximab required IV infusions, which typically involve prolonged visits to hospitals or clinics. The newly approved SC formulation leverages advanced drug delivery technology to maintain comparable efficacy and safety profiles while allowing for administration by patients themselves or caregivers in a home or outpatient setting.

Drug Name: Sarclisa Escena (generic name: isatuximab-irfc)
Mechanism of Action: A monoclonal antibody binding to the CD38 antigen on multiple myeloma cells.
Administration Route: Subcutaneous injection, a shift from previous intravenous infusion.
Benefits: Reduced administration time, decreased frequency of hospital visits, enhanced patient convenience, and improved quality of life.

The development of this SC formulation directly addresses patient needs for less burdensome treatment regimens. Clinical trials likely confirmed the bioequivalence, safety, and efficacy of the subcutaneous route compared to the intravenous administration. This provides patients with a more comfortable and manageable treatment option that better integrates into their daily lives.

Background & Context

Multiple myeloma is a relapsing and remitting cancer of plasma cells that often requires long-term treatment. While advances in therapy have improved outcomes, the associated physical and time burdens, particularly from frequent and lengthy IV infusions, have been substantial for patients. The introduction of an SC formulation for isatuximab represents a crucial step in fulfilling this unmet need, transforming myeloma care to be more sustainable and patient-centric.

Strategic Significance & Outlook

The approval of Sarclisa Escena is expected to facilitate a paradigm shift in multiple myeloma treatment, potentially improving patient adherence, treatment persistence, and ultimately, clinical outcomes. This trend toward more convenient, patient-friendly formulations is likely to extend to other monoclonal antibodies and oncology treatments. For Sanofi, this new formulation enhances its competitive position in the lucrative multiple myeloma market, demonstrating a commitment to patient-centered innovation.

Source: https://www.drugs.com/newdrugs.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.